NTRB
NASDAQ · Pharmaceuticals
Nutriband Inc
$5.52
-0.56 (-9.21%)
Financial Highlights (FY 2026)
Revenue
2.15M
Net Income
-8,671,912
Gross Margin
27.8%
Profit Margin
-404.1%
Rev Growth
-0.7%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 27.8% | 27.8% | 54.8% | 54.8% |
| Operating Margin | -408.4% | -367.6% | 14.3% | 15.1% |
| Profit Margin | -404.1% | -383.9% | 12.0% | 11.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.15M | 2.16M | 21.69M | 16.36M |
| Gross Profit | 596.9K | 601.1K | 11.89M | 8.96M |
| Operating Income | -8,766,569 | -7,944,730 | 3.11M | 2.47M |
| Net Income | -8,671,912 | -7,858,947 | 2.61M | 1.89M |
| Gross Margin | 27.8% | 27.8% | 54.8% | 54.8% |
| Operating Margin | -408.4% | -367.6% | 14.3% | 15.1% |
| Profit Margin | -404.1% | -383.9% | 12.0% | 11.5% |
| Rev Growth | -0.7% | -0.7% | +19.5% | +23.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 816.0K | 816.0K | 24.66M | 23.39M |
| Total Equity | 33.04M | 33.04M | 37.36M | 36.10M |
| D/E Ratio | 0.02 | 0.02 | 0.66 | 0.65 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -8,560,293 | -8,188,780 | 4.63M | 3.66M |
| Free Cash Flow | — | — | 2.95M | 1.96M |